Daniela Gabbia

 

Department of Pharmaceutical and Pharmacological Sciences, University of Padova Largo Meneghetti, 2, 35131 Padova - Italy

Current Position: Assistant Professor SSD BIO/14

Teaching Toxicology, 48 hours, 6 CFU

Contacts
Phone: +39-049-827-5079
e-mail: daniela.gabbia@unipd.it

  Short CV

2009 Master Degree (magna cum laude) in Pharmaceutical Chemistry and Technology. University of Pavia 

03/2010-12/2010 Research fellow: Department of Environmental Medicine and Public Health, Institute of Hygiene, University of Padova 

2014 PhD Degree in Pharmacological Sciences, curriculum Pharmacology, Toxicology and Therapeutics. Department of Pharmaceutical and Pharmacological Sciences, University of Padova (Italy). Thesis Title: “Effect of liver disease on hepatic enzyme induction: CYP1A and CYP3A inducibility in cirrhotic rats”.

2014-2021 PostDoc fellow: Department of Pharmaceutical and Pharmacological Sciences, University of Padova.

2022-present Assistant Professor. Department of Pharmaceutical and Pharmacological Sciences, University of Padova

Main fields of interest:

Drug metabolism, pharmacokinetic and toxicokinetic.  Pathologic aspects of liver diseases, in particular that underlying hepatic dysfunction progression of chronic liver disease with different etiologies to hepatocellular carcinoma.  Immunology, in particular investigation of the role of macrophage and T cell development in different liver diseases and in the modulation of immune tumor microenvironment.

Teaching

  Courses

Educational offer

  Office hours Gabbia

please contact daniela.gabbia@unipd.it

  Availability for Thesis Projects

Pre-clinical and Clinical evaluation of novel agents for chronic liver disease.
Characterization of animal models of liver diseases, e.g. NAFLD/NASH, fibrosis and HCC, with a focus on their immune phenotyping
Availability of internship position: please contact daniela.gabbia@unipd.it

Research

  Scientific Activities

The main research is focused on the preclinical evaluation of new substances of natural origin to be used for the therapy of non-alcoholic fatty liver disease (NAFLD) and its complication, steatohepatitis (NASH) and of novel formulations for the treatment of hepatocellular carcinoma. We are  studying different approaches: 1) evaluating the efficacy of natural and synthetic compounds on NAFLD/NASH, deepening the comprehension of the function of multiple dysfunctional pathways in the liver; 2) assessing their efficacy on preventing NAFLD/NASH progression; 3) investigating the molecular mechanisms involved of the progression of NASH into hepatocellular carcinoma, testing novel strategies to preventing this transition.

  Technical expertise

In vivo pharmacokinetic and toxicological studies. Animal studies with mouse and rat.

Cell culture techniques both with primary and immortalized cell lines.

Enzymatic assays.

Molecular and cellular biology techniques: qRT-PCR, Western blot, ELISA, immunohistochemistry, immunocytochemistry.

  Publications

  1. Gabbia D, Dall'Acqua S, Di Gangi IM, Bogialli S, Caputi V, Albertoni L, Marsilio I, Paccagnella N, Carrara M, Giron MC, De Martin S. The Phytocomplex from Fucus vesiculosus and Ascophyllum nodosum Controls Postprandial Plasma Glucose Levels: An In Vitro and In Vivo Study in a Mouse Model of NASH. Mar Drugs. 2017 Feb 15;15(2). pii: E41. doi: 10.3390/md15020041. IF 6.085
  2. Gabbia D, Pozza AD, Albertoni L, Lazzari R, Zigiotto G, Carrara M, Baldo V, Baldovin T, Floreani A, De Martin S. Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis. World J Gastroenterol. 2017 Nov 14;23(42):7519-7530. doi: 10.3748/wjg.v23.i42.7519. IF 5.374
  3. Gabbia D, Roverso M, Guido M, Sacchi D, Scaffidi M, Carrara M, Orso G, Russo FP, Floreani A, Bogialli S, De Martin S. Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis. Nutrients. 2019 Jul 15;11(7):1602. doi: 10.3390/nu11071602. IF 6.706
  4. Gabbia D, Saponaro M, Sarcognato S, Guido M, Ferri N, Carrara M, De Martin S. Fucus vesiculosus and Ascophyllum nodosum Ameliorate Liver Function by Reducing Diet-Induced Steatosis in Rats. Mar Drugs. 2020 Jan 17;18(1):62. doi: 10.3390/md18010062. IF 6.085
  5. De Martin S, Gabbia D, Folli F, Bifari F, Fiorina P, Ferri N, Stahl S, Inturrisi CE, Pappagallo M, Traversa S, Manfredi PL. REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study. Front Pharmacol. 2021 Apr 28;12:671859. doi: 10.3389/fphar.2021.671859. IF 5.988
  6. Gabbia D, Carpi S, Sarcognato S, Cannella L, Colognesi M, Scaffidi M, Polini B, Digiacomo M, Salsano JE, Manera C, Macchia M, Nieri P, Carrara M, Russo FP, Guido M, De Martin S. The Extra Virgin Olive Oil polyphenol Oleocanthal exerts antifibrotic effects in the liver. Front. Nutr. doi: 10.3389/fnut.2021.715183 IF 6.590
  7. Sayaf K, Zanotto I, Russo FP, Gabbia D*, De Martin S. The Nuclear Receptor PXR in Chronic Liver Disease. Cells. 2021 Dec 27;11(1):61. doi:10.3390/cells11010061. IF 7.666 *corresponding author
  8. Gabbia D, Roverso M, Sarcognato S, Zanotto I, Ferri N, Russo FP, Guido M, Bogialli S, De Martin S. The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. Biology (Basel). 2022 Apr 30;11(5):693. doi:10.3390/biology11050693. IF 5.168
  9. Gabbia D, Roverso M, Zanotto I, Colognesi M, Sayaf K, Sarcognato S, Arcidiacono D, Zaramella A, Realdon S, Ferri N, Guido M, Russo FP, Bogialli S, Carrara M, De Martin S. A Nutraceutical Formulation Containing Brown Algae Reduces Hepatic Lipid Accumulation by Modulating Lipid Metabolism and Inflammation in Experimental Models of NAFLD and NASH. Mar Drugs. 2022 Sep 8;20(9):572. doi: 10.3390/md20090572. IF 6.085
  10. Vaccarin C, Gabbia D$, Franceschinis E, De Martin S, Roverso M, Bogialli S, Sacchetti G, Tupini C, Lampronti I, Gambari R, Cabrini G, Dechecchi MC, Tamanini A, Marzaro G, Chilin A. Improved Trimethylangelicin Analogs for Cystic Fibrosis: Design, Synthesis and Preliminary Screening. Int J Mol Sci. 2022 Sep 29;23(19):11528. doi: 10.3390/ijms231911528 IF 6.208   $co-first author
  11. Gabbia D, Carpi S, Sarcognato S, Zanotto I, Sayaf K, Colognesi M, Polini B, Digiacomo M, Macchia M, Nieri P, Carrara M, Cazzagon N, Russo FP, Guido M, De Martin S. The phenolic compounds tyrosol and hydroxytyrosol counteract liver fibrogenesis via the transcriptional modulation of NADPH oxidases and oxidative stress-related miRNAs. Biomed Pharmacother. 2023 Jan;157:114014. doi: 10.1016/j.biopha.2022.114014. IF 7.419
  12. Gabbia D, De Martin S. Tumor Mutational Burden for Predicting Prognosis and Therapy Outcome of Hepatocellular Carcinoma. Int J Mol Sci. 2023 Feb 8;24(4):3441. doi: 10.3390/ijms24043441. IF 6.208

  Complete list of publications

Daniela Gabbia in Padua Research Archive IRIS (Institutional Research Information System)

  Research projects and Funds

Roche per la Ricerca 2019 – Project entitled: “Boosting nivolumab with cyclophosphamide for the immunotherapy of hepatocellular carcinoma: preclinical evaluations”